The decision for this additional recommendation was based on the strength of emerging evidence (largely published after the development of the NICE guidance) suggesting a higher cardiovascular risk such as stroke, cardiovascular death and myocardial infarction with diclofenac than other tNSAIDs and selective COX-2 inhibitors [8,22,23]. The gene discussed is PTGS2; the disease is Stroke.